Injectable Extended-Release Buprenorphine Treatment in the Fentanyl Era

May 19, 2020

Loading Events
  • This event has passed.
Watch Now View Presentation Slides

Presenter(s): John Mariani, MD, Associate Professor of Clinical Psychiatry, Columbia University Medical Center, New York, NY

Target Audience: Physicians, clinical nurse specialists, nurses (LPN/RN), nurse practitioners or other advanced practice nurses, PAs and healthcare teams.

Cost: No fee.

Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, and Interprofessional Continuing Education (IPCE) credit

Webinar Description: Extended-release injectable buprenorphine products are becoming available commercially; however there is minimal clinical experience with using these products in patients with opioid use disorder. It is essential for healthcare professionals to understand and be aware of new treatment modalities for OUD to share with patients as part of treatment options. Opioids remain the leading cause of fatal overdose in the US, and highly potent synthetic opioids are the most common opioid responsible for fatal overdoses, the rate of which continues to increase. This webinar will present data on the current state of opioid use disorder in the US, review injectable extended release buprenorphine products as well as the use of extended-release buprenorphine products for patients using fentanyl, and discuss the possible role for these treatments.

Educational Objectives:

  • Review the data supporting the use of injectable extended-release buprenorphine treatment for opioid use disorder.
  • Identify special risks that fentanyl use presents and the possible role of injectable extended release buprenorphine treatment.
  • Discuss the role of extended-release injectable buprenorphine in the treatment of OUD patients using fentanyl.

Joint Accreditation Statement

Jointly Accredited ProviderIn support of improving patient care, this activity has been planned and implemented by American Academy of Addiction Psychiatry (AAAP) and American Psychiatric Association (APA). AAAP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE) Designation Statement

IPCE CreditThis activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education credits for learning and change.

Physician Designation Statement

American Academy of Addiction Psychiatry designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation Statement

American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP’s Joint Accreditation provider #4008192. This activity is approved for up to 1 Nursing Contact Hours.

PA Designation Statement

American Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for a maximum of 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Details

Date:
May 19
Time:
12:00 pm - 1:00 pm
Event Category:

Other

Presenter
John Mariani, MD, Associate Professor of Clinical Psychiatry, Columbia University Medical Center, New York, NY
Time Zone
ET